

Clinical trials of intensive therapy for diabetes type 2 in all type of patients

TrialResults-center www.trialresultscenter.org

1 a

Trial	Treatments	Patients	Trials design and methods
vs			
Study 3002 n=NA follow-up:	-	-	
Study 3006 n=NA follow-up:	-	-	
Study 3102 n=NA follow-up:	-	-	
Study 4001 n=NA follow-up:	-	-	
Study 4002 n=NA follow-up:	-	-	
Study 4012 n=NA follow-up:	-	-	
Study 4013 n=NA follow-up:	-	-	
insulin detemir vs glargine			
Fadini , 2011 n=NA	-	-	
insulin lispro protamine suspension plus lispro vs glargine plus lispro			
Koivisto , 2011 n=NA	-	-	
insulin glargine plus insulin glulisine vs premixed insulin analogues			
Levin , 2011 n=NA	-	-	

References

Study 3002, 0:

Study 3006, 0:

Study 3102, 0:

Study 4001, 0:

Study 4002, 0:

Study 4012, 0:

Study 4013, 0:

Fadini, 2011:

Fadini GP, de Kreutzenberg SV, Mariano V, Boscaro E, Bertolini F, Mancuso P, Quarna J, Marescotti M, Agostini C, Tiengo A, Avogaro A, Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. *Diabetes Obes Metab* 2011;13:718-25. [21410861] [10.1111/j.1463-1326.2011.01396.x](https://doi.org/10.1111/j.1463-1326.2011.01396.x)

Koivisto, 2011:

Koivisto V, Cleall S, Pontiroli AE, Giugliano D, Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. *Diabetes Obes Metab* 2011;13:1149-57. [21819517] [10.1111/j.1463-1326.2011.01484.x](https://doi.org/10.1111/j.1463-1326.2011.01484.x)

Levin, 2011:

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R, Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. *Clin Ther* 2011;33:841-50. [21719107] [10.1016/j.clinthera.2011.05.091](https://doi.org/10.1016/j.clinthera.2011.05.091)

2 induced HbA1c reduction

Trial	Treatments	Patients	Trials design and methods
glitazone vs conventional treatment			
PROactive , 2005 [NCT00174993] n=2605/2633 follow-up: 34.5 months	pioglitazone titrated 15-45 mg daily versus standard treatment	patients with type 2 diabetes who had evidence of macrovascular disease	Parallel groups double blind 19 countries
intensive glycemic control vs conventional treatment			
ACCORD , 2008 [NCT00000620] n=5128/5123 follow-up: 3.5y (5y)	very intensive glycemic control through currently available means (targeting a glycosylated hemoglobin <6%) during a mean of 3.7 years versus standard glycemic control (targeting a glycosylated hemoglobin 7.0-7.9%)	patients with type 2 diabetes mellitus at high risk of death and stroke (pre-existing heart disease or two or more additional risk factors for heart disease)	Factorial plan open USA, Canada
ADDITION , 2010 [NCT00237549] n=1678/1379 follow-up: 5 year	intensive multifactorial treatment versus routine care	patients with newly diagnosed type 2 diabetes	Parallel groups open Denmark, United Kingdom, the Netherlands
ADVANCE , 2008 [NCT00145925] n=5571/5569 follow-up: median 5 y	intensive glucose-lowering treatments HbA1C <=6.5% using gliclazide(modified release) plus other drugs versus standard glucose-lowering treatments (targetglycated hemoglobin levels defined on the basisof local guidelines)	patients with type 2 diabetes	Parallel groups open 20 countries

continued...

Trial	Treatments	Patients	Trials design and methods
Kumamoto (primary prev) , 1995 n=28/27 follow-up: 8.0y	intensive glycemic control with multiple insulin injection treatment versus conventional insulin injection treatment (1-2 daily injections)	patients with non-insulin-dependent diabetes mellitus and with no retinopathy and urinary albumin excretions <30 mg/24 h	Parallel groups open Japan
Kumamoto (secondary prev) , 1995 n=27/28 follow-up: 8.0y	multiple insulin injection treatment versus conventional insulin injection treatment (1-2 daily injections)	patients with non-insulin-dependent diabetes mellitus and simple retinopathy	Parallel groups open Japan
Steno 2 , 2003 n=80/80 follow-up: 7.8 y	targeted, intensified, multifactorial intervention versus conventional treatment on modifiable risk factors for cardiovascular disease	patients with type 2 diabetes and microalbuminuria	Parallel groups open Denmark
UKPDS 33 , 1998 n=2729/1138 follow-up: 10.3 y	intensive policy with a sulphonylurea (chlorpropamide, glibenclamide, or glipizide) or with insulin; fasting plasma glucose <6.0 mmol/L versus conventional policy with diet	newly diagnosed patients with type 2 diabetes who after 3 months diet treatment had a mean of two fasting plasma glucose concentrations of 61150 mmol/L	Parallel groups open UK
VA CSDM , 1997 n=75/78 follow-up: 2.3y	intensive glycemic control (stepped plan from 1 evening injection of insulin, alone or with glipizide, to multiple daily injections, target to attain near-normal glycemia levels) versus standard treatment (1 insulin injection every morning)	non-insulin-dependent diabetes mellitus patients	Parallel groups open USA
VADT , 2008 [NCT00032487] n=892/899 follow-up: 5.6y	intensive glucose control versus standard glucose control	military veterans who had a suboptimal response to therapy for type 2 diabetes	Parallel groups open US

References

PROactive, 2005:

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. *Diabetes Care* 2004;27:1647-53 [[15220241](#)]

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokn M, Norkus A, Pirags V, Po Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89 [[16214598](#)] [10.1016/S0140-6736\(05\)67528-9](#)

Wilcox R, Kupfer S, Erdmann E Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). *Am Heart J* 2008;155:712-7 [[18371481](#)] [10.1016/j.ahj.2007.11.029](#)

ACCORD, 2008:

Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59 [[18539917](#)]

Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99:4i-20i [[17599424](#)]

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. *N Engl J Med* 2010 Jun 29;: [[20587587](#)] [10.1056/NEJMoa1001288](#)

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010 Jun 29;: [[20594588](#)] [10.1016/S0140-6736\(10\)60576-4](#)

Klein BE Reduction in Risk of Progression of Diabetic Retinopathy. *N Engl J Med* 2010 Jun 29;: [[20587586](#)] [10.1056/NEJMe1005667](#)

Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med* 2011 Mar 3;364:818-28 [[21366473](#)] [10.1056/NEJMoa1006524](#)

ADDITION, 2010:

Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, Borch-Johnsen K, Wareham NJ, Lauritzen T Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. *Diabetologia* 2008;51:1127-34 [[18443762](#)] [10.1007/s00125-008-1013-0](#)

Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. *Lancet* 2011 Jun 24;: [[21705063](#)] [10.1016/S0140-6736\(11\)60698-3](#)

ADVANCE, 2008:

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560-72 [[18539916](#)]

Kumamoto (primary prev), 1995:

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995;28:103-17 [[7587918](#)]

Kumamoto (secondary prev), 1995:

Shichiri M, Kishikawa H, Ohkubo Y, Wake N Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000;23 Suppl 2:B21-9 [[10860187](#)]

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995;28:103-17 [[7587918](#)]

Steno 2, 2003:

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383-93 [[12556541](#)]

UKPDS 33, 1998:

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837-53 [[9742976](#)]

VA CSDM, 1997:

Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. *Arch Intern Med* 1997;157:181-8 [[9009975](#)]

VADT, 2008:

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. *N Engl J Med* 2008 Dec 17;: [[19092145](#)]

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.